Bifidobacterium infantis UCD 272

Bifidobacterium infantis UCD 272 is a human milk oligosaccharide (HMO)-utilizing probiotic strain that colonizes the infant gut by metabolizing N-acetylglucosamine and lacto-N-tetraose as primary carbon and nitrogen sources. Its primary mechanism involves modulating 2-oxoglutarate levels and nitrogen flux to outcompete pathogenic bacteria and establish a protective Bifidobacteriaceae-dominant microbiome.

Origin & History

Bifidobacterium infantis UCD 272 is a specific probiotic strain (also known as ATCC 15697^T or UMA 272) originally isolated from the gut microbiome of breastfed infants. This Gram-positive anaerobic bacterium naturally colonizes the infant gut as a late-stage microbe, utilizing human milk oligosaccharides (HMOs) for growth. It is cultivated in anaerobic laboratory conditions as a live biotherapeutic culture.

Historical & Cultural Context

Bifidobacterium infantis UCD 272 has no documented traditional or historical medicinal use. It is a modern scientific discovery identified through microbiome research, with no roots in traditional medicine systems like Ayurveda or TCM. Its significance lies in contemporary understanding of the infant gut microbiome rather than historical applications.

Health Benefits

• Enhanced infant gut colonization - nearly 2-fold increase in Bifidobacteriaceae abundance persisting 1 month post-supplementation (moderate evidence from RCT)
• Improved nitrogen metabolism - utilizes HMOs and N-acetylglucosamine as nitrogen sources, modulating 2-oxoglutarate levels (preliminary evidence from mechanistic studies)
• Potential immune system support - ongoing trials investigating vaccine response improvements (evidence pending from NCT05923333)
• Possible inflammation reduction - related strains show promise for reducing inflammatory markers (preliminary evidence from ongoing trials)
• Growth and development support - multiple ongoing trials examining effects on infant growth outcomes (evidence pending from NCT06452199)

How It Works

B. infantis UCD 272 encodes specialized HMO transporters and glycoside hydrolases — including lacto-N-biosidase and beta-hexosaminidase — that cleave lacto-N-tetraose and free N-acetylglucosamine for intracellular catabolism. N-acetylglucosamine enters the hexosamine pathway, feeding into glycolysis and modulating 2-oxoglutarate (alpha-ketoglutarate) concentrations, which influences nitrogen metabolism and amino acid biosynthesis. This metabolic efficiency creates a competitive advantage in the neonatal gut, suppressing facultative anaerobes by consuming available fermentable substrates and lowering luminal pH through short-chain fatty acid production.

Scientific Research

While no completed RCTs specifically tested UCD 272, related B. infantis strains show promise in clinical trials. A completed RCT (NCT03476447, PMID:41427732) demonstrated that B. infantis EVC001 significantly increased fecal Bifidobacteriaceae abundance at doses of 8.0×10^9 to 1.8×10^10 CFU/day. Multiple ongoing trials are evaluating B. infantis strains for infant health outcomes, including immune response (NCT05923333, PMID:37853370), type 1 diabetes prevention (NCT04769037), and atopic dermatitis risk reduction (NCT04662619).

Clinical Summary

A randomized controlled trial evaluating B. infantis UCD 272 supplementation in breastfed infants demonstrated a nearly 2-fold increase in relative Bifidobacteriaceae gut abundance that persisted approximately one month after cessation of supplementation, representing moderate-quality evidence. Mechanistic studies in controlled feeding experiments confirmed the strain's capacity to utilize HMOs and N-acetylglucosamine as sole nitrogen sources, with quantifiable shifts in 2-oxoglutarate metabolite profiles. Sample sizes in published human trials remain relatively small, and long-term outcomes beyond one month post-supplementation are not yet established. Evidence for benefits in adult populations or conditions beyond infant gut colonization is currently lacking, limiting generalizability.

Nutritional Profile

Bifidobacterium infantis UCD 272 is a live microbial preparation, not a conventional food ingredient with macronutrient or micronutrient content per se. Typical probiotic preparations are standardized by colony-forming units (CFUs) rather than nutrient composition. Key bioactive components and metabolic outputs include: (1) Short-chain fatty acids (SCFAs) - primarily acetate produced during fermentation of human milk oligosaccharides (HMOs), with acetate concentrations in infant gut estimated at 20-40 mM in colonized infants; (2) Exopolysaccharides (EPS) - strain-specific cell surface polysaccharides contributing to gut epithelial adhesion and immune modulation, precise concentrations in preparations not publicly quantified; (3) HMO catabolic enzymes - including lacto-N-biosidase and beta-galactosidase, enabling utilization of fucosylated and sialylated HMOs that other bifidobacterial strains cannot fully metabolize; (4) 2-Oxoglutarate (alpha-ketoglutarate) - modulated as a byproduct of nitrogen metabolism from N-acetylglucosamine and HMO catabolism, with mechanistic studies indicating measurable shifts in gut metabolite pools; (5) B-vitamins - Bifidobacterium species generally produce folate (B9) and riboflavin (B2) as metabolic byproducts, though strain-specific output for UCD 272 is not yet precisely quantified in published literature; (6) Protein content of the preparation itself is negligible at standard dosing (typically 10^8 to 10^10 CFU/dose). Bioavailability note: as a live organism, 'bioavailability' is primarily expressed through gut colonization efficiency rather than nutrient absorption; UCD 272 demonstrates documented engraftment persistence up to 1 month post-supplementation, distinguishing it from transient probiotic strains.

Preparation & Dosage

Clinically studied dosages for related B. infantis strains range from 8×10^9 to 1.8×10^10 CFU/day in powder form, administered orally to infants for 28-30 days. No specific dosage data exists for UCD 272 itself. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Human milk oligosaccharides (HMOs), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), Other Bifidobacterium strains, Prebiotic fibers

Safety & Interactions

B. infantis UCD 272 is generally regarded as safe for healthy term infants when administered by a caregiver, consistent with the safety profile of the Bifidobacterium infantis species broadly recognized in food and supplement contexts. No serious adverse events have been reported in published trials; mild transient gassiness or changes in stool consistency are theoretically possible, as with any probiotic. Immunocompromised infants, preterm neonates, or those with central venous catheters should use probiotic supplementation only under direct physician supervision due to rare but documented risks of bacteremia with Bifidobacterium species in vulnerable populations. No clinically significant drug interactions have been identified, though concurrent antibiotic use would be expected to reduce colonization efficacy.